Vorapaxar for HIV-associated inflammation and coagulopathy (ADVICE): a randomised, double-blind, placebo-controlled trial

Add time:07/11/2019    Source:sciencedirect.com

SummaryBackgroundIncreased D-dimer concentrations are associated with poor cardiovascular and other clinical outcomes in people with treated HIV infection. Proteinase activated receptor-1 (PAR-1) is activated by thrombin and overexpressed by immune cells from HIV-infected people. We aimed to study the efficacy of vorapaxar, a licensed inhibitor of PAR-1, in reducing HIV-associated hypercoagulation and inflammation.

We also recommend Trading Suppliers and Manufacturers of Vorapaxar Sulfate (cas 705260-08-8). Pls Click Website Link as below: cas 705260-08-8 suppliers

Prev:Sugarcane bagasse hydrolysate as a potential feedstock for red pigment production by Monascus ruber
Next:Peripheral Revascularization in Patients With Peripheral Artery Disease With Vorapaxar)